Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 3,200 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 3,200 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $39.91, for a total value of $127,712.00. Following the completion of the sale, the insider directly owned 84,515 shares of the company’s stock, valued at $3,372,993.65. This represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Castle Biosciences Stock Performance

CSTL stock traded down $2.56 during midday trading on Thursday, hitting $32.40. 763,751 shares of the company traded hands, compared to its average volume of 405,892. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $44.28. The stock has a market capitalization of $945.76 million, a price-to-earnings ratio of -72.00 and a beta of 1.06. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02. The business has a 50 day simple moving average of $39.67 and a 200-day simple moving average of $29.50.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.32. The business had revenue of $80.55 million for the quarter, compared to analyst estimates of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. As a group, equities research analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on CSTL shares. Robert W. Baird boosted their price objective on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research report on Monday, December 29th. Guggenheim lifted their price objective on Castle Biosciences from $43.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, January 26th. KeyCorp restated an “overweight” rating and issued a $50.00 target price on shares of Castle Biosciences in a research note on Thursday, January 29th. Finally, Canaccord Genuity Group lifted their price target on shares of Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Castle Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.14.

Institutional Trading of Castle Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC lifted its holdings in Castle Biosciences by 139,100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after buying an additional 1,391 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of Castle Biosciences during the third quarter worth $35,000. CWM LLC lifted its stake in shares of Castle Biosciences by 80.6% during the third quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after acquiring an additional 853 shares during the period. Jones Financial Companies Lllp boosted its holdings in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after acquiring an additional 297 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.